John Talley (chemist)

John J. Talley is an American medicinal chemist who was the lead chemist in the discovery of the COX-2 selective nonsteroidal anti-inflammatory drug celecoxib and a co-inventor of amprenavir, a protease inhibitor used to treat HIV infection.[1][2]

He earned his BA at the University of Northern Iowa and his PhD in chemistry from the University of Minnesota. From 1979 to 1986 he worked at the General Electric R&D center in Schenectady, New York then joined the Searle division of Monsanto, where he led the team that discovered celecoxib, as well as other marketed COX-2 inhibitors valdecoxib, parecoxib, and mavacoxib, as well as amprenavir which licensed by Searle to Vertex Pharmaceuticals.[2][3] In 2002 he was hired by Microbia to lead their antifungal drug discovery efforts.[4][1][5] He left the company in 2008.[6]

References
  1. Langreth, Robert (June 23, 2003). "The Chemical Cobbler". Forbes.
  2. "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. St. Louis Section, American Chemical Society. 52 (5): 2. May 2001. Archived from the original (PDF) on 15 April 2018.
  3. "Press release: UNI alumni and friends honored at Distinguished Awards Celebration". UNI Foundation. November 18, 2015.
  4. Withers, Melissa (September 22, 2004). "Drug hunters". Paradigm Magazine, Whitehead Institute.
  5. McCarthy, Alice A. (February 2003). "Microbia" (PDF). Chemistry & Biology. 10 (2): 99–100. doi:10.1016/S1074-5521(03)00031-0. PMID 12618178.
  6. "John J. Talley profile". Bloomberg. Retrieved 15 April 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.